5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is widely regarded as one of the most potent psychedelic substances known to science. Unlike its structural relative N,N-DMT, which is famous for elaborate fractal visuals and "entity contact," 5-MeO-DMT produces an experience defined by overwhelming ego dissolution, oceanic boundlessness, and states frequently described as "white light" or "the void" -- with comparatively little visual geometry .
The compound occurs naturally in the parotid gland secretions of the Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius). A single toad yields roughly 0.25-0.5 g of dried venom, of which up to 15% may be 5-MeO-DMT -- enough for several effective doses at just 3-5 mg when vaporized . The first formal identification of B. alvarius secretion as psychoactive was published by Weil and Davis in 1994, though anecdotal use appears to predate that report .
Beyond the toad, 5-MeO-DMT has been found in numerous plant species, including Anadenanthera peregrina (yopo) seeds and Virola bark, and it is also an endogenous compound in humans. It has been detected in human cerebrospinal fluid, blood, and urine, and may be synthesized in the pineal gland and retina via the enzyme indolethylamine-N-methyltransferase (INMT) . Its endogenous role remains poorly understood, though elevated concentrations have been associated with certain psychotic states .
Pharmacologically, 5-MeO-DMT stands apart from most classical psychedelics through its preferential affinity for the 5-HT1A receptor (Ki ~3 nM) over the 5-HT2A receptor (Ki ~907 nM) -- roughly a 300-fold selectivity difference . This 5-HT1A predominance likely accounts for its unique phenomenological signature: the rapid, total dissolution of self-referential processing rather than the complex visual distortions characteristic of 5-HT2A-driven psychedelics like LSD or psilocybin . It also binds to sigma-1 receptors and the serotonin transporter (SERT), adding further complexity to its mechanism of action .
When vaporized, onset is nearly instantaneous (15-60 seconds), with peak effects lasting 10-20 minutes and a total duration of roughly 30-45 minutes. The experience is often described as the most intense psychedelic state attainable -- a "complete reset" that, in clinical and ceremonial settings, has shown promising associations with reductions in depression, anxiety, and PTSD symptoms .
References
Reckweg JT, et al. The clinical pharmacology and potential therapeutic applications of 5-MeO-DMT. Journal of Neurochemistry. 2022;162(2):128-146. Weil AT, Davis W. Bufo alvarius: a potent hallucinogen of animal origin. Journal of Ethnopharmacology. 1994;41(1-2):1-8. Shen HW, et al. Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions. Current Drug Metabolism. 2010;11(8):659-666. Nichols DE. Psychedelics. Pharmacological Reviews. 2016;68(2):264-355. Uthaug MV, et al. A single inhalation of vapor from dried toad secretion containing 5-MeO-DMT in a naturalistic setting is related to sustained enhancement of satisfaction with life. Psychopharmacology. 2019;236:2653-2666.
Safety at a Glance
High Risk- Harm Reduction Guidelines for 5-MeO-DMT
- Critical Contraindications
- Toxicity: Safety Profile The acute toxicity of 5-MeO-DMT when used alone in appropriate doses appears to be relatively low in o...
- Dangerous with: PCP, Cocaine
- Overdose risk: Overdose and Emergency Presentation Recognizing a Medical Emergency Not every intense 5-MeO-DMT e...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
smoked
insufflated
Duration
smoked
Total: 20 min – 40 mininsufflated
Total: 2 hrs – 3 hrsHow It Feels
Nothing in the psychedelic canon truly prepares one for the onset of 5-MeO-DMT. When vaporized, it arrives within seconds — not as a gradual unfolding but as an obliteration. Between the moment of exhalation and the moment the experience fully takes hold, perhaps ten to fifteen seconds elapse, and in that brief window the entirety of ordinary consciousness is swept away with a violence that is physiological as much as psychological. The body convulses with sensation: an overwhelming pressure builds from within, as though every cell is vibrating at a frequency the organism was not designed to sustain. The heart pounds, breathing becomes involuntary and ragged, and there is a sensation of heat or electricity flooding through every nerve pathway simultaneously.
What follows is not an experience in any conventional sense, because the apparatus that normally experiences — the sense of being a self, looking outward at a world — is simply absent. There are no geometric patterns, no entity encounters, no visual landscapes. Instead, there is a white-hot totality: an infinite, undifferentiated field of consciousness that has no center, no edges, and no observer. The term ego death is used across psychedelic literature, but in the context of 5-MeO-DMT it is less a metaphor and more a clinical description. The boundary between self and everything else does not soften or thin — it ceases to exist. What remains is variously described as void, source, God, or the ground of being, but all such descriptions are retrospective attempts to name something that, in the moment, is beyond language entirely.
The body during this state may writhe, vocalize, or become completely still. From outside, the person may appear to be in ecstasy or agony — and indeed, the experience often contains elements of both, fused together in a way that transcends the usual pleasure-pain dichotomy. There can be moments of terror so pure they become indistinguishable from rapture. The physical intensity is extraordinary: nausea, trembling, sweating, and a sense that the body is being turned inside out are all commonly reported. The peak lasts five to twenty minutes but time perception is completely abolished, so it may feel like an eternity or no time at all.
The return to ordinary consciousness is abrupt and disorienting. Within fifteen to thirty minutes of the initial inhalation, the sense of self reconstitutes — often accompanied by sobbing, laughter, or stunned silence. The body feels wrung out, trembling, soaked in sweat. There is frequently a period of profound emotional release, as though something that had been compressed for a lifetime has suddenly been allowed to expand. The afterglow can last hours to days and is often characterized by a deep, quiet peace, a sense of having touched something fundamental and irrevocable. Many describe it as the most significant experience of their lives.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(5)
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Visual(2)
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Visual exposure to semantic concept network— A high-level hallucinatory state in which the observer perceives a vast, interconnected web of geome...
Cognitive(4)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
Transpersonal(6)
- Dissolution of boundaries— Progressive blurring and dissolution of the boundary between self and external reality, merging one'...
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Perception of eternalism— The experience that all moments across the timeline of existence are equally real and simultaneously...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Pharmacodynamics 5-MeO-DMT is a methoxylated derivative of dimethyltryptamine (DMT). While most common psychedelics are believed to primarily elicit psychological effects through agonism of serotonin 5-HT2A receptors, 5-MeO-DMT shows 1,000-fold greater affinity for the serotonin 5-HT1A receptor over the serotonin 5-HT2A receptor. In line with its affinity for serotonin 5-HT1A receptors, 5-MeO-DMT is extremely potent at suppressing the firing of dorsal raphe nucleus serotonin neurons. Further, its activity in rats was attenuated with the selective serotonin 5-HT1A receptor antagonist WAY-100635, while selective serotonin 5-HT2A receptor antagonist volinanserin failed to demonstrate any change. Additional mechanisms of action such as inhibition of monoamine reuptake may also be involved in its effects.
Similarly to other serotonergic psychedelics, 5-MeO-DMT is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors, among others. It shows pronounced biased agonism at the serotonin 5-HT2C receptor. The drug is 4- to 10-fold more potent as a hallucinogen than DMT in humans. In contrast to most serotonergic psychedelics however, it has been said that it is unclear that the hallucinogenic effects of 5-MeO-DMT are principally mediated by activation of the serotonin 5-HT2A receptor. In any case, 5-MeO-DMT does still activate the serotonin 5-HT2A receptor and does still produce psychedelic effects. It has been proposed that 5-MeO-DMT be considered an "atypical" psychedelic. This relates to the fact that 5-MeO-DMT has 100- to 1,000-fold selectivity for the serotonin 5-HT1A receptor over the serotonin 5-HT2A receptor and that the actions of 5-MeO-DMT appear to be primarily mediated by serotonin 5-HT1A receptor activation. For example, the potencies of drugs substituting for 5-MeO-DMT in drug discrimination assays is well-correlated with their serotonin 5-HT1A receptor affinities, and the discriminative stimulus effects of 5-MeO-DMT are almost completely blocked (~80%) by serotonin 5-HT1A receptor antagonists like WAY-100,635. However, there is partial generalization of 5-MeO-DMT to the selective serotonin 5-HT2 receptor agonist (–)-DOM in animals. In addition, the selective serotonin 5-HT2A receptor antagonist volinanserin subtly reduces (~20%) the 5-MeO-DMT interoceptive cue, suggesting a minor contribution of this receptor. Selective antagonists of other serotonin receptors, including the serotonin 5-HT1B, 5-HT2B, and 5-HT2C receptors, had no effect on the discriminative stimulus effects of 5-MeO-DMT. In accordance with the preceding findings, which suggest effects mediated primarily by the serotonin 5-HT1A receptor and to a lesser extent by the serotonin 5-HT2A receptor, 5-MeO-DMT is reported to produce distinct subjective effects compared to DMT and other psychedelics in humans.
Although 5-MeO-DMT shows dramatically higher affinity for the serotonin 5-HT1A receptor than for the serotonin 5-HT2A receptor, the situation appears to be very different in terms of its actual activational potencies at these receptors. Its EC50Tooltip half-maximal effective concentration values have been found to be 1.80 to 3.87nM at the serotonin 5-HT2A receptor and 3.92 to 1,060nM at the serotonin 5-HT1A receptor. For comparison, the EC50 values of DMT were found to be 38.3nM at the serotonin 5-HT2A receptor and >10,000nM at the serotonin 5-HT1A receptor in one of the same studies. Hence, 5-MeO-DMT appears to be similarly potent or as much as 200-fold more potent as an agonist of the serotonin 5-HT2A receptor than of the serotonin 5-HT1A receptor. In addition, 5-MeO-DMT is 10-fold more potent than DMT as an agonist of the serotonin 5-HT2A receptor.
Besides serotonin receptors, 5-MeO-DMT is an agonist of the melatonin MT1 and MT2 receptors. Unlike DMT, 5-MeO-DMT is not a ligand or agonist of the sigma receptors. In contrast to certain other tryptamines, 5-MeO-DMT is inactive as a monoamine releasing agent, including of serotonin, norepinephrine, and dopamine. However, it is a weak serotonin reuptake inhibitor, with an IC50Tooltip half-maximal inhibitory concentration value of 2,184nM. Conversely, it is inactive as a dopamine and norepinephrine reuptake inhibitor (IC50 = >10,000nM).
Similarly to DMT, but in contrast to most other psychedelics, like LSD and psilocybin, there appears to be very little development of tolerance with 5-MeO-DMT. In fact, there may even be sensitization to the effects of 5-MeO-DMT. The lack of tolerance development with 5-MeO-DMT may be due to biased agonism of the serotonin 5-HT2A receptor. More specifically, 5-MeO-DMT activates the Gq signaling pathway of the serotonin 5-HT2A receptor with much less potency in recruiting β-arrestin2. Activation of β-arrestin2 is linked to receptor downregulation and tachyphylaxis.
Pharmacokinetics Absorption 5-MeO-DMT is not orally active and must be administered parenterally.
Distribution 5-MeO-DMT is lipophilic and is thought to easily cross the blood–brain barrier. Accordingly, 5-MeO-DMT readily accumulates in the brain in animals with levels higher than in blood. This is in notable contrast to bufotenin (5-HO-DMT or N,N-dimethylserotonin) and serotonin (5-HT), which are hydrophilic and have varying degrees of peripheral selectivity.
Metabolism Bufotenin is an active metabolite of 5-MeO-DMT, formed by O-demethylation by cytochrome P450 CYP2D6. Bufotenin notably has much higher affinity for the serotonin 5-HT2A receptor than 5-MeO-DMT itself. However, bufotenin does not seem to be extensively produced from 5-MeO-DMT in the brain. In addition, peripherally formed bufotenin is less able to exert central effects due to its relative peripheral selectivity in terms of crossing into the brain. Hence, the involvement of bufotenin in the psychoactive effects of 5-MeO-DMT is uncertain.
The metabolism of 5-MeO-DMT can be dramatically reduced and its levels markedly augmented and prolonged by monoamine oxidase inhibitors (MAOIs). In addition, MAOIs allow 5-MeO-DMT to become orally active in humans. Combining 5-MeO-DMT with MAOIs has sometimes resulted in serotonin syndrome and death in humans.
Elimination The elimination half-life of 5-MeO-DMT, administered sublingually, was found to be 28minutes.
Detection Methods
Urine Detection
5-MeO-DMT is not targeted by standard immunoassay-based urine drug screens. 5-MeO-substituted tryptamines are metabolized primarily through hepatic pathways involving CYP2D6 and monoamine oxidase enzymes, producing demethylated and hydroxylated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect these metabolites in urine for approximately 24 to 48 hours after ingestion, though the detection window varies with dose and individual metabolic rate. The short duration of action of most 5-MeO tryptamines correlates with a relatively brief detection window.
Blood and Serum Detection
Blood detection windows for 5-MeO-DMT are short, typically 2 to 8 hours after administration depending on the route. Smoked or insufflated routes produce rapid peak concentrations followed by swift clearance, while oral administration (particularly with MAO inhibition) extends both the effect and detection windows. LC-MS/MS is required for reliable blood quantification at the low nanogram-per-milliliter concentrations typical of 5-MeO tryptamines.
Standard Drug Panel Inclusion
5-MeO-DMT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. 5-MeO tryptamines do not cross-react with any standard immunoassay panel targets. There is no reliable cross-reactivity with amphetamine, opiate, or any other standard immunoassay. Detection requires a specific request for tryptamine testing at a laboratory with novel psychoactive substance capabilities.
Confirmatory Methods
Definitive identification of 5-MeO-DMT requires LC-MS/MS or GC-MS analysis with compound-specific reference standards. Some forensic toxicology laboratories include 5-MeO-DMT in their expanded tryptamine panels, but coverage of other 5-MeO variants is less common. Bufotenin (5-HO-DMT), a metabolite of 5-MeO-DMT, may also be targeted. Quantitative analysis requires validated methods, as the structural similarity among 5-MeO tryptamines can complicate chromatographic separation without optimized conditions.
Reagent Testing (Harm Reduction)
The Ehrlich reagent produces a purple to violet reaction with 5-MeO-DMT, confirming the presence of an indole ring characteristic of all tryptamines. This is the primary field identification tool and should always be the first test performed. The Hofmann reagent provides a confirmatory blue reaction. The Marquis reagent typically shows no reaction or a faint yellow to brown discoloration with 5-MeO tryptamines. Because 5-MeO tryptamines can be significantly more potent by weight than 4-substituted analogs, reagent testing alone is not sufficient for safe use. Quantitative analysis and accurate dosing are critically important for this subclass.
Interactions
| Substance | Status | Note |
|---|---|---|
| PCP | Dangerous | — |
| Cocaine | Unsafe | — |
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-x | Uncertain | — |
| 2C-x | Uncertain | — |
| Cannabis | Uncertain | — |
| DOx | Uncertain | — |
| MDMA | Uncertain | — |
History
The history of 5-MeO-DMT is intertwined with the broader story of psychedelic research, which has oscillated between periods of intense scientific interest and strict prohibition.
Like many psychedelic compounds, 5-MeO-DMT was either synthesized in a laboratory setting or identified as a naturally occurring psychoactive substance through ethnobotanical research. The mid-20th century saw an explosion of interest in psychedelic compounds, with researchers exploring their potential applications in psychotherapy, creativity enhancement, and the study of consciousness.
The political and cultural backlash of the late 1960s and early 1970s led to the criminalization of most psychedelic substances, effectively halting legitimate research for decades. The resurgence of psychedelic research beginning in the 2000s — often called the "psychedelic renaissance" — has renewed scientific interest in this class of compounds, with clinical trials exploring applications in treatment-resistant depression, PTSD, end-of-life anxiety, and addiction.
5-MeO-DMT exists within this broader pharmacological and cultural context, with its specific history shaped by its date of discovery, legal status, availability, and unique pharmacological profile.
Community and Cultural Context
The growing popularity of 5-MeO-DMT in psychedelic communities has been accompanied by the emergence of ceremonial and therapeutic use contexts, particularly in retreat settings. Community discussions reflect both enthusiasm for the compound's therapeutic potential and concern about the proliferation of poorly trained facilitators offering 5-MeO-DMT experiences without adequate safety protocols.
The compound's association with the Sonoran Desert toad has created a unique conservation dimension to community discourse. As demand for toad venom has increased, community members have raised alarm about declining toad populations and the environmental impact of commercial collection. This has contributed to a community-wide shift toward advocating for synthetic 5-MeO-DMT as the preferred source.
Harm Reduction
Harm Reduction Guidelines for 5-MeO-DMT
Critical Contraindications
MAOIs are absolutely contraindicated. This is the single most important safety rule for 5-MeO-DMT. Monoamine oxidase inhibitors -- including pharmaceutical MAOIs (phenelzine, tranylcypromine), the harmala alkaloids found in ayahuasca (harmine, harmaline, tetrahydroharmine), and Syrian rue (Peganum harmala) -- block the primary metabolic pathway for 5-MeO-DMT, dramatically increasing exposure and creating life-threatening serotonin toxicity . If you have recently participated in an ayahuasca ceremony or consumed any MAOI-containing substance, you must wait a minimum of 24 hours (ideally 48+ hours) before using 5-MeO-DMT.
Other serotonergic medications are also dangerous in combination: SSRIs, SNRIs, lithium, tramadol, dextromethorphan, and St. John's wort all increase serotonin syndrome risk. If you are on any psychiatric medication, consult a physician before considering 5-MeO-DMT.
Always Have a Sitter
5-MeO-DMT frequently causes complete physical incapacitation -- loss of motor control, involuntary movement, temporary cessation of breathing awareness, and total unresponsiveness to external stimuli. A sober, experienced sitter is not optional; it is essential. The sitter should be prepared to :
- Maintain an open airway and roll the person onto their side if vomiting occurs
- Provide physical safety during thrashing or involuntary movement
- Monitor breathing and be prepared to initiate rescue breathing if needed
- Remain calm and provide reassurance without excessive stimulation
- Call emergency services if severe symptoms (prolonged apnea, seizures, extreme hyperthermia) develop
Dosage Guidelines
For synthetic 5-MeO-DMT (freebase, vaporized) :
- Threshold: 1-3 mg
- Light: 3-5 mg
- Common: 5-12 mg
- Strong: 12-20 mg
- Heavy: 20+ mg (extremely inadvisable without extensive experience)
Use a milligram-precision scale. The margin between a moderate and overwhelming experience is a few milligrams. Volumetric dosing solutions can improve accuracy at low doses. For Bufo toad secretion, dosing is inherently less precise because 5-MeO-DMT concentration varies between specimens (typically 5-15% of dried venom weight) .
Set, Setting, and Screening
Choose a quiet, comfortable environment free from hazards (sharp objects, hard surfaces, bodies of water). Remove obstacles the person could collide with during involuntary movement. Medical screening for cardiovascular conditions, seizure disorders, and psychiatric history (particularly psychotic disorders) is strongly recommended before use. Individuals with a personal or family history of schizophrenia, bipolar disorder, or psychotic episodes should avoid 5-MeO-DMT.
Integration
The 5-MeO-DMT experience can be profoundly destabilizing. Many users describe it as the most intense experience of their lives. Post-experience integration support -- whether through a therapist, integration circle, or experienced guide -- is strongly recommended to process the psychological material that surfaces .
References
Jiang XL, et al. Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine. Journal of Pharmacology and Experimental Therapeutics. 2013;345(1):10-16. Psychedelic Society UK. 5-MeO-DMT: Harm Reduction Advice. psychedelicsociety.org.uk. DanceSafe. 5-MeO-DMT. dancesafe.org. Weil AT, Davis W. Bufo alvarius: a potent hallucinogen of animal origin. Journal of Ethnopharmacology. 1994;41(1-2):1-8. Uthaug MV, et al. A single inhalation of vapor from dried toad secretion containing 5-MeO-DMT. Psychopharmacology. 2019;236:2653-2666.
Toxicity & Safety
Safety Profile
The acute toxicity of 5-MeO-DMT when used alone in appropriate doses appears to be relatively low in otherwise healthy individuals, but it carries specific physiological risks that demand respect and awareness.
Cardiovascular Effects
5-MeO-DMT reliably produces transient cardiovascular stimulation, including elevated heart rate (tachycardia) and elevated blood pressure (hypertension). A 2025 study in Scientific Reports examining the cardiac effects of DMT and 5-MeO-DMT confirmed direct effects on cardiac tissue, including potential increases in contractile force and heart rate . For individuals with pre-existing cardiovascular conditions, hypertension, or cardiac arrhythmias, these effects represent a genuine risk.
Serotonin Syndrome
The most serious acute danger is serotonin syndrome, particularly when 5-MeO-DMT is combined with monoamine oxidase inhibitors (MAOIs), SSRIs, SNRIs, or other serotonergic drugs. Serotonin syndrome presents as a triad of neuromuscular excitation (tremor, clonus, rigidity), autonomic instability (hyperthermia, tachycardia, diaphoresis), and altered mental status (agitation, confusion) . Animal studies demonstrate that co-administration with the MAOI harmaline dramatically potentiates 5-MeO-DMT-induced hyperthermia and can produce fatal serotonin toxicity .
Documented Fatalities
Deaths attributed to 5-MeO-DMT are rare but documented. A well-known fatal case involved ingestion of 5-MeO-DMT within an ayahuasca preparation containing harmala alkaloids (MAOIs), underscoring that the combination -- not the substance alone -- was the proximate cause . Other reported fatalities have typically involved polydrug use, pre-existing medical conditions, or unsupervised settings where respiratory compromise went unaddressed.
Physical Safety Considerations
During the acute experience, users frequently become physically incapacitated -- writhing, thrashing, or becoming completely unresponsive. This creates secondary risks including aspiration (if vomiting occurs while supine), falls, and injury. In animal models, high doses produced ataxia, mydriasis, tremor, convulsions, and respiratory depression .
References
Cardiac effects of two hallucinogenic natural products, N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine. Scientific Reports. 2025;15:91400. Shen HW, et al. Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions. Current Drug Metabolism. 2010;11(8):659-666. Jiang XL, et al. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline. Neuropharmacology. 2015;91:205-213. Sklerov J, et al. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. Journal of Analytical Toxicology. 2005;29(8):838-841.
Addiction Potential
Not physically addictive. Tolerance develops. No withdrawal syndrome. Low abuse liability. The intensity of the experience often self-limits frequent use.
Overdose Information
Overdose and Emergency Presentation
Recognizing a Medical Emergency
Not every intense 5-MeO-DMT experience is an overdose -- the substance reliably produces overwhelming psychological states even at normal doses. However, certain physical signs indicate a genuine medical emergency requiring immediate intervention :
- Severe tachycardia (heart rate sustained above 150 bpm)
- Pronounced hypertension or signs of cardiovascular distress
- Hyperthermia (body temperature rising above 39C / 102F) -- this is a hallmark of serotonin syndrome and can be fatal
- Muscle rigidity, particularly generalized rigidity or opisthotonus
- Seizures or sustained myoclonus (repetitive, involuntary muscle jerking)
- Prolonged apnea (cessation of breathing beyond 30 seconds)
- Loss of consciousness with loss of protective reflexes
Serotonin Syndrome
If 5-MeO-DMT has been combined with any serotonergic substance (MAOIs, SSRIs, MDMA, tramadol), serotonin syndrome must be suspected. The classic triad includes neuromuscular hyperactivity (clonus, tremor, hyperreflexia), autonomic dysfunction (hyperthermia, tachycardia, diaphoresis), and mental status changes (agitation, delirium). This is a life-threatening emergency -- untreated severe serotonin syndrome has a significant mortality rate .
When to Call Emergency Services
Call emergency services (911) immediately if any of the following occur:
- Seizures
- Breathing stops or becomes extremely labored
- Body temperature feels dangerously hot
- Muscle rigidity is severe
- The person is unresponsive and cannot be roused after the expected duration (>30 minutes for vaporized administration)
- Any sign of serotonin syndrome in the context of polydrug use
While waiting for help: place the person in the recovery position (on their side), ensure the airway is clear, monitor breathing, and do not administer fluids orally to an unconscious person. Be honest with paramedics about what was consumed .
References
Shen HW, et al. Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions. Current Drug Metabolism. 2010;11(8):659-666. Boyer EW, Shannon M. The serotonin syndrome. New England Journal of Medicine. 2005;352(11):1112-1120. CAHMA. Safer Using - 5-MeO-DMT. cahma.org.au.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Tolerance
| Full | almost immediately after ingestion |
| Half | 1 hour |
| Zero | 2 hours |
Cross-tolerances
Legal Status
Legal Status
United States
5-MeO-DMT was placed into Schedule I of the Controlled Substances Act effective January 19, 2011, following a final rule published by the DEA in the Federal Register on December 20, 2010 . This classifies it alongside heroin, LSD, and MDMA as having "high potential for abuse, no currently accepted medical use in treatment, and a lack of accepted safety for use under medical supervision." Manufacturing, distribution, dispensing, importation, exportation, and possession are all federal criminal offenses.
Prior to 2011, 5-MeO-DMT existed in a legal gray area in the United States -- it was not specifically scheduled, though prosecution was possible under the Federal Analogue Act by arguing structural similarity to already-scheduled tryptamines like DMT.
United Kingdom
5-MeO-DMT is a Class A, Schedule 1 controlled substance under the Misuse of Drugs Act 1971. Possession, production, and supply carry severe penalties, including up to 7 years for possession and life imprisonment for supply .
Other Countries
- Canada: Not specifically scheduled under the Controlled Drugs and Substances Act, though may be prosecuted as an analogue
- Australia: Controlled as an analogue of DMT under federal scheduling
- Germany: Controlled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG) and BtMG
- Sweden: Classified as a narcotic substance
- Finland: Banned since December 2014
- Russia: Controlled since October 2011
- China: Listed as a controlled substance
- Mexico: Not explicitly scheduled, leading to a legal gray area that has enabled toad ceremony retreats, though enforcement status varies
- Brazil: Not specifically listed, though general analogue provisions may apply
Conservation Note
The increasing popularity of Bufo toad ceremonies has raised serious conservation concerns for Incilius alvarius, whose wild populations in the Sonoran Desert are under pressure from collection for venom harvesting .
References
DEA Final Rule. Schedules of Controlled Substances: Placement of 5-Methoxy-N,N-Dimethyltryptamine into Schedule I. Federal Register. 2010;75(243):79296-79300. UK Misuse of Drugs Act 1971, Schedule 2 (Class A drugs). Psychedelic Alpha. Worldwide Psychedelic Laws database. Psychedelics Today. The Ethical and Ecological Considerations of Inhaling Bufotoxins from Incilius Alvarius. 2018.
Experience Reports (6)
Tips (10)
Combining 5-MeO-DMT with MAOIs (including ayahuasca, Syrian rue, or pharmaceutical MAOIs) is potentially fatal. Unlike N,N-DMT which benefits from MAOIs, 5-MeO-DMT is already orally active and the combination causes life-threatening serotonin syndrome.
NEVER combine 5-MeO-DMT with MAOIs, harmine, or harmaline. Unlike N,N-DMT, this combination with 5-MeO-DMT has caused deaths. This includes ayahuasca brews. There is no safe way to combine these.
A sober sitter is absolutely mandatory for 5-MeO-DMT. Users frequently thrash, vocalize loudly, and lose all awareness of their physical body. Without a sitter, there is a real risk of injury from falling or striking objects during the peak.
5-MeO-DMT is NOT the same as N,N-DMT. It is significantly more physically and psychologically intense. Typical breakthrough doses are 5-15mg vaporized. Using DMT doses of 5-MeO would be extremely dangerous.
5-MeO-DMT is widely considered the most intense psychedelic substance available. Unlike N,N-DMT, it produces a complete dissolution of self and reality rather than elaborate visual landscapes. Many describe it as experiencing the perspective of pure consciousness.
A trained sitter is not optional with 5-MeO-DMT. Intense physical reactions are common: thrashing, screaming, arching the back, and complete loss of body awareness. People have injured themselves without a sitter present.
Community Discussions (8)
A user shares an inspiring third-party account of profound self-discovery following a 5-MeO-DMT experience, describing realizations about identity, ego dissolution, and inner peace. The post highlights the substance's capacity for deep therapeutic and spiritual insight.
A user describes losing an enormous stash of various research chemicals including a-PVP, 4-FA, 2-FMA, ETH-LAD, ALD-52, multiple dissos, benzos, and other compounds. The post serves as a nostalgic inventory of RC availability from a prior era.
The author describes vaporizing 5mg of 5-MeO-DMT and experiencing an intense, terrifying dissolution of self that felt like dying, far beyond prior experiences. Despite the harrowing nature, the user acknowledges the importance of surrender and finds some meaning in the experience after recovering.
A user provides a brief preliminary report on 5-MeO-MET, noting it has a subtle, rushing quality at 5-10mg smoked and differs meaningfully from 5-MeO-MiPT despite similar dosing. They promise a more complete analysis in a future post.
A user asks whether combining Syrian Rue (full inhibition MAOI dose) with 20mg MET intranasally is dangerous, acknowledging that 5-MeO-DMT with MAOIs can be fatal and seeking guidance on safer tryptamine combinations. The question explores risk levels of MAOI-potentiated tryptamines.
A user shares practical vaporization temperature data for 5-MeO-DMT derived from enail experiments, finding optimal results between 550-650°F with a maximum effective temperature of 800°F. This serves as a useful harm reduction reference for those using enails.
A user compares the freebase vaporized experience of three cathinone stimulants (4F-PHP, MDPHP, APHP), rating MDPHP and 4F-PHP above APHP for euphoria when properly freebased and vaporized. The post notes that many negative reviews of 4F-PHP stem from users vaporizing the HCl salt rather than the freebase.
The author reflects on how 5-MeO-DMT produced a visual experience of translucent rainbow light resembling the appearance of DMT entities, suggesting the substance may offer a glimpse into what it is like to inhabit a more energetic or subtle form of existence. The post is philosophical and experiential in nature.
Further Reading
Hamilton Morris
American chemist, journalist, and filmmaker whose documentary series Hamilton's Pharmacopeia brought rigorous scientific storytelling about psychoactive substances to mainstream television.
Read articleRick Strassman
American psychiatrist who conducted the first government-approved human research with a psychedelic substance in over twenty years, administering DMT to sixty volunteers and coining the term 'the spirit molecule.'
Read articleEgo Dissolution & the Mystical Experience
Ego dissolution -- the temporary loss of the sense of self -- is the defining feature of the psychedelic experience. Research shows it is reliably associated with therapeutic outcomes and can be measured, predicted, and understood in neural terms.
Read articlePiHKAL & TiHKAL: The Shulgins' Chemical Love Stories
Alexander and Ann Shulgin's twin masterworks -- PiHKAL (1991) and TiHKAL (1997) -- are part autobiography, part love story, and part synthesis manual. Together they document the creation and testing of over 230 psychoactive compounds, forming the most comprehensive pharmacological self-experiment in scientific history.
Read articleHow to Change Your Mind by Michael Pollan
Michael Pollan's 2018 bestseller brought psychedelic science out of the academic margins and into mainstream conversation. By combining rigorous reporting, personal experimentation, and accessible prose, Pollan did for psilocybin and LSD what he had previously done for food: made Americans rethink something fundamental.
Read articleSee Also
References (6)
- 5-MeO-DMT Vault - Erowid
Erowid experience vault for 5-MeO-DMT
erowid - Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: 5-MeO-DMT
PubChem compound page for 5-MeO-DMT (CID: 1832)
pubchem - 5-MeO-DMT - TripSit Factsheet
TripSit factsheet for 5-MeO-DMT
tripsit - 5-MeO-DMT - Wikipedia
Wikipedia article on 5-MeO-DMT
wikipedia
Gallery